Leukocytosis: Difference between revisions

Jump to navigation Jump to search
Line 210: Line 210:
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematologic
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematologic
! align="center" style="background:#DCDCDC;" |[[Granulocytosis|Hereditary neutrophilia]]<ref name="HerringSmith1974">{{cite journal|last1=Herring|first1=William Benjamin|last2=Smith|first2=Laurin Gresham|last3=Walker|first3=Richard Isley|last4=Herion|first4=John Carroll|title=Hereditary neutrophilia|journal=The American Journal of Medicine|volume=56|issue=5|year=1974|pages=729–734|issn=00029343|doi=10.1016/0002-9343(74)90642-1}}</ref>
! align="center" style="background:#DCDCDC;" |[[Granulocytosis|Hereditary neutrophilia]]<ref name="HerringSmith1974">{{cite journal|last1=Herring|first1=William Benjamin|last2=Smith|first2=Laurin Gresham|last3=Walker|first3=Richard Isley|last4=Herion|first4=John Carroll|title=Hereditary neutrophilia|journal=The American Journal of Medicine|volume=56|issue=5|year=1974|pages=729–734|issn=00029343|doi=10.1016/0002-9343(74)90642-1}}</ref>
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Unknown
* Unknown
* Germline [[mutation]] in [[CSF3R]]
* Germline [[mutation]] in [[CSF3R]]
Line 220: Line 220:
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Rare [[Dominance relationship|autosomal dominant]] genetic disorder
| align="center" style="background:#F5F5F5;" + |Rare [[Dominance relationship|autosomal dominant]] genetic disorder
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Positive family history
* Positive family history
| align="center" style="background:#F5F5F5;" + |Normal
| align="center" style="background:#F5F5F5;" + |Normal
Line 234: Line 234:
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Normal [[Granulocyte|granulocytes]]
* Normal [[Granulocyte|granulocytes]]
* [[Histiocyte|Histiocytes]] of Gaucher type
* [[Histiocyte|Histiocytes]] of Gaucher type
Line 242: Line 242:
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Molecular testing
| align="center" style="background:#F5F5F5;" + |Molecular testing
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* High [[leukocyte alkaline phosphatase]]
* High [[leukocyte alkaline phosphatase]]
* Progress to [[leukemia]]
* Progress to [[leukemia]]
Line 257: Line 257:
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Elderly
| align="center" style="background:#F5F5F5;" + |Elderly
| align="center" style="background:#F5F5F5;" + |Exposure to
| align="left" style="background:#F5F5F5;" + |Exposure to
*[[Chemotherapy]]
*[[Chemotherapy]]
*[[Radiation therapy]]
*[[Radiation therapy]]
*[[Tobacco smoking|Tobacco smoke]]
*[[Tobacco smoking|Tobacco smoke]]
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Petechia|Petechiae]]
* [[Petechia|Petechiae]]
* [[Purpura]]
* [[Purpura]]
Line 272: Line 272:
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
*[[Shortness of breath]]
*[[Shortness of breath]]
*[[Fatigue]]
*[[Fatigue]]
Line 278: Line 278:
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↑/↓
| align="center" style="background:#F5F5F5;" + |↑/↓
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
*Large [[Platelet|platelets]]
*Large [[Platelet|platelets]]
*Ovalomacrocytosis
*Ovalomacrocytosis
Line 285: Line 285:
*Pelger-Huet anomaly
*Pelger-Huet anomaly
*Ring [[Sideroblastic anemia|sideroblasts]]
*Ring [[Sideroblastic anemia|sideroblasts]]
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
*Impaired [[myeloid]] maturation
*Impaired [[myeloid]] maturation
*[[Congenital dyserythropoietic anemia|Dyserythropoiesis]]
*[[Congenital dyserythropoietic anemia|Dyserythropoiesis]]
Line 296: Line 296:
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + clinical manifestation
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + clinical manifestation
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
*[[Thrombosis]] at unusual sites
*[[Thrombosis]] at unusual sites
*[[Thrombosis]] in younger patients
*[[Thrombosis]] in younger patients
Line 302: Line 302:
|-
|-
! align="center" style="background:#DCDCDC;" |[[Polycythemia vera]]<ref name="pmid26336886">{{cite journal |vauthors=Boiocchi L, Gianelli U, Iurlo A, Fend F, Bonzheim I, Cattaneo D, Knowles DM, Orazi A |title=Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications |journal=Mod. Pathol. |volume=28 |issue=11 |pages=1448–57 |date=November 2015 |pmid=26336886 |doi=10.1038/modpathol.2015.100 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Polycythemia vera]]<ref name="pmid26336886">{{cite journal |vauthors=Boiocchi L, Gianelli U, Iurlo A, Fend F, Bonzheim I, Cattaneo D, Knowles DM, Orazi A |title=Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications |journal=Mod. Pathol. |volume=28 |issue=11 |pages=1448–57 |date=November 2015 |pmid=26336886 |doi=10.1038/modpathol.2015.100 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
*Autonomous [[Red blood cell|erythrocyte]] production
*Autonomous [[Red blood cell|erythrocyte]] production
*[[JAK2]] mutation (> 95%)
*[[JAK2]] mutation (> 95%)
Line 312: Line 312:
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |Mean age >60 years old
| align="center" style="background:#F5F5F5;" + |Mean age >60 years old
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
*[[Stroke]]
*[[Stroke]]
*[[Visual system|Visual disturbance]]
*[[Visual system|Visual disturbance]]
Line 324: Line 324:
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
*Painful [[erythema]]
*Painful [[erythema]]
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |↑  
| align="center" style="background:#F5F5F5;" + |↑  
| align="center" style="background:#F5F5F5;" + |↑  
| align="center" style="background:#F5F5F5;" + |↑  
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
*Elevated normochromic, normocytic [[Red blood cell|RBCs]]
*Elevated normochromic, normocytic [[Red blood cell|RBCs]]
*[[Thrombocytosis]]
*[[Thrombocytosis]]
*≥ 10% immature myeloid precursors
*≥ 10% immature myeloid precursors
*Leukoerythroblastic picture
*Leukoerythroblastic picture
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Increased myeloid:erythroid ratio due to granulocytic proliferation
* Increased myeloid:erythroid ratio due to granulocytic proliferation
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
Line 340: Line 340:
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + clinical manifestation
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + clinical manifestation
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
*[[Stroke]]
*[[Stroke]]
*[[Venous thrombosis]]
*[[Venous thrombosis]]
Line 347: Line 347:
|-
|-
! align="center" style="background:#DCDCDC;" |[[Microangiopathic hemolytic anemia]] (MAHA)<ref name="pmid27288467">{{cite journal |vauthors=Morton JM, George JN |title=Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer |journal=J Oncol Pract |volume=12 |issue=6 |pages=523–30 |date=June 2016 |pmid=27288467 |doi=10.1200/JOP.2016.012096 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Microangiopathic hemolytic anemia]] (MAHA)<ref name="pmid27288467">{{cite journal |vauthors=Morton JM, George JN |title=Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer |journal=J Oncol Pract |volume=12 |issue=6 |pages=523–30 |date=June 2016 |pmid=27288467 |doi=10.1200/JOP.2016.012096 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Microvascular disease|Microangiopathy]]
* [[Microvascular disease|Microangiopathy]]
* [[Leukemoid reaction]]
* [[Leukemoid reaction]]
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
Line 358: Line 357:
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Coagulopathy|Bleeding disorder]]
* [[Coagulopathy|Bleeding disorder]]
* Positive family history
* Positive family history
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Pallor]]
* [[Pallor]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
Line 376: Line 375:
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Fragmented [[Red blood cell|RBCs]]
* Fragmented [[Red blood cell|RBCs]]
* [[Red blood cell|Schistocytes]]  
* [[Red blood cell|Schistocytes]]  
Line 384: Line 383:
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + clinical manifestation
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + clinical manifestation
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Non-immune [[hemolysis]]
* Non-immune [[hemolysis]]
* Elevated [[Lactate dehydrogenase|LDH]]
* Elevated [[Lactate dehydrogenase|LDH]]
Line 392: Line 391:
|-
|-
! align="center" style="background:#DCDCDC;" |Leukoerythroblastosis<ref name="pmid25562031">{{cite journal |vauthors=Canbolat Ayhan A, Timur C, Ayhan Y, Kes G |title=Leukoerythroblastosis Mimicking Leukemia: A case report |journal=Iran J Pediatr |volume=24 |issue=3 |pages=332–3 |date=June 2014 |pmid=25562031 |pmc=4276592 |doi= |url=}}</ref>
! align="center" style="background:#DCDCDC;" |Leukoerythroblastosis<ref name="pmid25562031">{{cite journal |vauthors=Canbolat Ayhan A, Timur C, Ayhan Y, Kes G |title=Leukoerythroblastosis Mimicking Leukemia: A case report |journal=Iran J Pediatr |volume=24 |issue=3 |pages=332–3 |date=June 2014 |pmid=25562031 |pmc=4276592 |doi= |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Space-occupying lesions in the [[bone marrow]]
* Space-occupying lesions in the [[bone marrow]]
* [[Infection]]
* [[Infection]]
Line 402: Line 401:
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Coagulopathy|Bleeding disorder]]
* [[Coagulopathy|Bleeding disorder]]
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Pallor]]
* [[Pallor]]
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
Line 413: Line 412:
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Early satiety
* Early satiety
* Fatigue
* Fatigue
Line 419: Line 418:
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Nucleated red cells
* Nucleated red cells
* [[Reticulocyte|Reticulocytosis]]
* [[Reticulocyte|Reticulocytosis]]
* [[Poikilocytosis|Poikilocytes]]
* [[Poikilocytosis|Poikilocytes]]
* Circulating immature [[White blood cells|white cells]], generally [[Myelocyte|myelocytes]] and [[Promyelocyte|promyelocytes]]
* Circulating immature [[White blood cells|white cells]], generally [[Myelocyte|myelocytes]] and [[Promyelocyte|promyelocytes]]
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Circulating immature [[White blood cells|white cells]], generally [[Myelocyte|myelocytes]] and [[Promyelocyte|promyelocytes]]
* Circulating immature [[White blood cells|white cells]], generally [[Myelocyte|myelocytes]] and [[Promyelocyte|promyelocytes]]
* [[Myelofibrosis]]
* [[Myelofibrosis]]
Line 431: Line 430:
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination|Bone marrow biopsy]]
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination|Bone marrow biopsy]]
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Marrow infiltrative disorders
* Marrow infiltrative disorders
* [[Physical trauma|Trauma]]
* [[Physical trauma|Trauma]]
Line 472: Line 471:
|-
|-
! align="center" style="background:#DCDCDC;" |[[Leukocyte adhesion deficiency]]<ref name="pmid26434744">{{cite journal |vauthors=Levy-Mendelovich S, Rechavi E, Abuzaitoun O, Vernitsky H, Simon AJ, Lev A, Somech R |title=Highlighting the problematic reliance on CD18 for diagnosing leukocyte adhesion deficiency type 1 |journal=Immunol. Res. |volume=64 |issue=2 |pages=476–82 |date=April 2016 |pmid=26434744 |doi=10.1007/s12026-015-8706-5 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Leukocyte adhesion deficiency]]<ref name="pmid26434744">{{cite journal |vauthors=Levy-Mendelovich S, Rechavi E, Abuzaitoun O, Vernitsky H, Simon AJ, Lev A, Somech R |title=Highlighting the problematic reliance on CD18 for diagnosing leukocyte adhesion deficiency type 1 |journal=Immunol. Res. |volume=64 |issue=2 |pages=476–82 |date=April 2016 |pmid=26434744 |doi=10.1007/s12026-015-8706-5 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Primary immunodeficiency]]
* [[Primary immunodeficiency]]
* Failure to express [[CD18]]
* Failure to express [[CD18]]
Line 482: Line 481:
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |Rare [[autosomal recessive]], [[Leukocyte adhesion deficiency|LAD]] II more in Middle East and Brazil  
| align="center" style="background:#F5F5F5;" + |Rare [[autosomal recessive]], [[Leukocyte adhesion deficiency|LAD]] II more in Middle East and Brazil  
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Positive family history
* Positive family history
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Characteristic facial appearance, short stature, limb malformations, and severe [[Developmental disability|developmental delay]] in [[Leukocyte adhesion deficiency|LAD]] II
* Characteristic facial appearance, short stature, limb malformations, and severe [[Developmental disability|developmental delay]] in [[Leukocyte adhesion deficiency|LAD]] II
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
Line 493: Line 492:
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Signs of different [[Infection|infections]]
* Signs of different [[Infection|infections]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓/↑
| align="center" style="background:#F5F5F5;" + |↓/↑
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Leukocytosis
* Leukocytosis
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Leukocytosis
* Leukocytosis
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
Line 506: Line 505:
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |[[Flow cytometry]]
| align="center" style="background:#F5F5F5;" + |[[Flow cytometry]]
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Recurrent [[Infection|bacterial infections]]
* Recurrent [[Infection|bacterial infections]]
* Delay in umbilical cord sloughing
* Delay in umbilical cord sloughing
* Inability to form [[Abscess|abscesses]]
* Inability to form [[Abscess|abscesses]]
|-
|-
! align="center" style="background:#DCDCDC;" |Cryopyrin-associated periodic syndromes<ref name="pmid30035647">{{cite journal |vauthors=Labrousse M, Kevorkian-Verguet C, Boursier G, Rowczenio D, Maurier F, Lazaro E, Aggarwal M, Lemelle I, Mura T, Belot A, Touitou I, Sarrabay G |title=Mosaicism in autoinflammatory diseases: Cryopyrin-associated periodic syndromes (CAPS) and beyond. A systematic review |journal=Crit Rev Clin Lab Sci |volume=55 |issue=6 |pages=432–442 |date=September 2018 |pmid=30035647 |doi=10.1080/10408363.2018.1488805 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |Cryopyrin-associated periodic syndromes<ref name="pmid30035647">{{cite journal |vauthors=Labrousse M, Kevorkian-Verguet C, Boursier G, Rowczenio D, Maurier F, Lazaro E, Aggarwal M, Lemelle I, Mura T, Belot A, Touitou I, Sarrabay G |title=Mosaicism in autoinflammatory diseases: Cryopyrin-associated periodic syndromes (CAPS) and beyond. A systematic review |journal=Crit Rev Clin Lab Sci |volume=55 |issue=6 |pages=432–442 |date=September 2018 |pmid=30035647 |doi=10.1080/10408363.2018.1488805 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Unknown
* Unknown
* [[Mutation]]
* [[Mutation]]
Line 523: Line 521:
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |[[Dominance relationship|Autosomal dominant]] autoinflammatory syndrome
| align="center" style="background:#F5F5F5;" + |[[Dominance relationship|Autosomal dominant]] autoinflammatory syndrome
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Positive family history
* Positive family history
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Hive-like rash without itching
* Hive-like rash without itching
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
Line 534: Line 532:
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Red eyes
* Red eyes
* [[Nausea and vomiting|Vomiting]]
* [[Nausea and vomiting|Vomiting]]
Line 541: Line 539:
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓/↑
| align="center" style="background:#F5F5F5;" + |↓/↑
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Leukocytosis
* Leukocytosis
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Leukocytosis
* Leukocytosis
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
Line 549: Line 547:
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Genetic tests
| align="center" style="background:#F5F5F5;" + |Genetic tests
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Blindness]]
* [[Blindness]]
* [[Hearing impairment|Hearing loss]]
* [[Hearing impairment|Hearing loss]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Rheumatoid arthritis]]<ref name="pmid20870100">{{cite journal |vauthors=Scott DL, Wolfe F, Huizinga TW |title=Rheumatoid arthritis |journal=Lancet |volume=376 |issue=9746 |pages=1094–108 |date=September 2010 |pmid=20870100 |doi=10.1016/S0140-6736(10)60826-4 |url=}}</ref><ref name="pmid24568138">{{cite journal |vauthors=Glant TT, Mikecz K, Rauch TA |title=Epigenetics in the pathogenesis of rheumatoid arthritis |journal=BMC Med |volume=12 |issue= |pages=35 |date=February 2014 |pmid=24568138 |pmc=3936819 |doi=10.1186/1741-7015-12-35 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Rheumatoid arthritis]]<ref name="pmid20870100">{{cite journal |vauthors=Scott DL, Wolfe F, Huizinga TW |title=Rheumatoid arthritis |journal=Lancet |volume=376 |issue=9746 |pages=1094–108 |date=September 2010 |pmid=20870100 |doi=10.1016/S0140-6736(10)60826-4 |url=}}</ref><ref name="pmid24568138">{{cite journal |vauthors=Glant TT, Mikecz K, Rauch TA |title=Epigenetics in the pathogenesis of rheumatoid arthritis |journal=BMC Med |volume=12 |issue= |pages=35 |date=February 2014 |pmid=24568138 |pmc=3936819 |doi=10.1186/1741-7015-12-35 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Immune mediated
* Immune mediated
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
Line 563: Line 561:
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any, more in young women, between 30-60 years old
| align="center" style="background:#F5F5F5;" + |Any, more in young women, between 30-60 years old
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Positive family history
* Positive family history
* Cigarette smoking
* Cigarette smoking
* [[Obesity]]
* [[Obesity]]
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Deformed joints
* Deformed joints
* Rheumatoid nodules
* Rheumatoid nodules
Line 577: Line 575:
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Weight loss]]
* [[Weight loss]]
* [[Fatigue]]
* [[Fatigue]]
Line 584: Line 582:
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Leukocytosis
* Leukocytosis
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |NA
Line 591: Line 589:
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + positive anti-CCP antibodies
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + positive anti-CCP antibodies
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Osteoporosis]]
* [[Osteoporosis]]
* [[Infection|Infections]]
* [[Infection|Infections]]
Line 599: Line 597:
|-
|-
! align="center" style="background:#DCDCDC;" |[[Juvenile rheumatoid arthritis|Juvenile onset rheumatoid arthritis]]<ref name="pmid23763801">{{cite journal |vauthors=Naz S, Mushtaq A, Rehman S, Bari A, Maqsud A, Khan MZ, Ahmad TM |title=Juvenile rheumatoid arthritis |journal=J Coll Physicians Surg Pak |volume=23 |issue=6 |pages=409–12 |date=June 2013 |pmid=23763801 |doi=06.2013/JCPSP.409412 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Juvenile rheumatoid arthritis|Juvenile onset rheumatoid arthritis]]<ref name="pmid23763801">{{cite journal |vauthors=Naz S, Mushtaq A, Rehman S, Bari A, Maqsud A, Khan MZ, Ahmad TM |title=Juvenile rheumatoid arthritis |journal=J Coll Physicians Surg Pak |volume=23 |issue=6 |pages=409–12 |date=June 2013 |pmid=23763801 |doi=06.2013/JCPSP.409412 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Immune mediated
* Immune mediated
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
Line 608: Line 606:
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Children under the age of 16
| align="center" style="background:#F5F5F5;" + |Children under the age of 16
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Positive family history
* Positive family history
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
** Blotchy rash on a child's arms and legs
*Blotchy rash on a child's arms and legs
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
Line 619: Line 617:
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Fatigue]]
* [[Fatigue]]
* Dry eyes and mouth
* Dry eyes and mouth
Line 625: Line 623:
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Leukocytosis
* Leukocytosis
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |NA
Line 632: Line 630:
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + laboratory findings
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + laboratory findings
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Uveitis]]
* [[Uveitis]]
* [[Infection|Infections]]
* [[Infection|Infections]]
Line 638: Line 636:
|-
|-
! align="center" style="background:#DCDCDC;" |[[Still's disease|Adult Still's disease]]
! align="center" style="background:#DCDCDC;" |[[Still's disease|Adult Still's disease]]
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Immune mediated
* Immune mediated
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
Line 648: Line 646:
| align="center" style="background:#F5F5F5;" + |Rare autoimmune disease
| align="center" style="background:#F5F5F5;" + |Rare autoimmune disease
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Nonpruritic salmon-colored [[rash]] (usually over trunk or extremities while [[Fever|febrile]])
* Nonpruritic salmon-colored [[rash]] (usually over trunk or extremities while [[Fever|febrile]])
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
Line 657: Line 655:
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* [[Headache]]
* [[Headache]]
* [[Pharyngitis|Sore throat]]
* [[Pharyngitis|Sore throat]]
Line 665: Line 663:
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Leukocytosis
* Leukocytosis
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |NA
Line 672: Line 670:
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion
| align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* High [[ferritin]]
* High [[ferritin]]
* Negative [[Antinuclear antibodies|ANA]]
* Negative [[Antinuclear antibodies|ANA]]
Line 679: Line 677:
|-
|-
! align="center" style="background:#DCDCDC;" |[[Kawasaki disease]]
! align="center" style="background:#DCDCDC;" |[[Kawasaki disease]]
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Immune mediated
* Immune mediated
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
Line 689: Line 687:
| align="center" style="background:#F5F5F5;" + |Autoimmune disease, more in Asian ethnicity boys
| align="center" style="background:#F5F5F5;" + |Autoimmune disease, more in Asian ethnicity boys
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Diffuse macular-papular erythematous rash in the genital area, and red eyes, lips, palms or soles of the feet
* Diffuse macular-papular erythematous rash in the genital area, and red eyes, lips, palms or soles of the feet
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +

Revision as of 21:00, 29 September 2018

WikiDoc Resources for Leukocytosis

Articles

Most recent articles on Leukocytosis

Most cited articles on Leukocytosis

Review articles on Leukocytosis

Articles on Leukocytosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Leukocytosis

Images of Leukocytosis

Photos of Leukocytosis

Podcasts & MP3s on Leukocytosis

Videos on Leukocytosis

Evidence Based Medicine

Cochrane Collaboration on Leukocytosis

Bandolier on Leukocytosis

TRIP on Leukocytosis

Clinical Trials

Ongoing Trials on Leukocytosis at Clinical Trials.gov

Trial results on Leukocytosis

Clinical Trials on Leukocytosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Leukocytosis

NICE Guidance on Leukocytosis

NHS PRODIGY Guidance

FDA on Leukocytosis

CDC on Leukocytosis

Books

Books on Leukocytosis

News

Leukocytosis in the news

Be alerted to news on Leukocytosis

News trends on Leukocytosis

Commentary

Blogs on Leukocytosis

Definitions

Definitions of Leukocytosis

Patient Resources / Community

Patient resources on Leukocytosis

Discussion groups on Leukocytosis

Patient Handouts on Leukocytosis

Directions to Hospitals Treating Leukocytosis

Risk calculators and risk factors for Leukocytosis

Healthcare Provider Resources

Symptoms of Leukocytosis

Causes & Risk Factors for Leukocytosis

Diagnostic studies for Leukocytosis

Treatment of Leukocytosis

Continuing Medical Education (CME)

CME Programs on Leukocytosis

International

Leukocytosis en Espanol

Leukocytosis en Francais

Business

Leukocytosis in the Marketplace

Patents on Leukocytosis

Experimental / Informatics

List of terms related to Leukocytosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2] Lakshmi Gopalakrishnan, M.B.B.S. [3]

Synonyms and keywords: Elevated white blood cell count; Right-shift leukocytosis; Left-leukocytosis

Overview

Leukocytosis is an elevation of the white blood cell count above the normal range (greater than 11,000 per mm3). Leukocytosis is frequently a sign of an inflammatory response, most commonly the result of infection, but may also occur following certain parasitic infections, bone tumors, strenuous exercise, emotional stress, pregnancy, anesthesia, and epinephrine administration. Leukocytosis may be classified into 5 subtypes: neutrophilia (most common), lymphocytosis, monocytosis, eosinophilia, and basophilia. Other classification, include: Left shift or right shift leucocytosis. The pathogenesis of leukocytosis is characterized by the increase of leukocytes (primarily neutrophils), followed by the proliferation and release of granulocyte and monocyte precursors in the bone marrow which is stimulated by several products of inflammation including C3a and G-CSF.[1]

Historical Perspective

  • Leukocytosis was first discovered by Paul Kautchakoff, in 1846.[1]

Classification

  • Leukocytosis may be classified into 5 subtypes:[2]
  • Leukocytosis may also be classified into 2 groups:[2]
  • Left shift (most common)
  • Immature leukocytes increase
  • Proliferation and release of granulocyte and monocyte precursors in the bone marrow
  • Usually stimulated by several products of inflammation including C3a and G-CSF
  • Right shift
  • Reduced count or lack of "young neutrophils"
  • Associated with the presence of "giant neutrophils
  • Other variant of leukocytosis is the leukemoid reaction.
  • The image below demonstrates a graphic figure that illustrates hematopoietic growth factors in leukocytosis.[3]

Pathophysiology

  • The pathogenesis of leukocytosis is characterized by:[2]
  • An increased release of leukocytes from bone marrow storage pools
  • Decreased margination of leukocytes onto vessel walls
  • Decreased extravasation of leukocytes from the vessels into tissues
  • Increase in number of precursor cells in the marrow

Causes

  • To see a comprehensive list of all causes of leukocytosis, please click here
Causes of leukocytosis
Neutrophilic
leukocytosis
(neutrophilia)
Eosinophilic
leukocytosis
(eosinophilia)
Basophilic
leukocytosis
Basophilia
Monocytosis
Lymphocytosis

Epidemiology and Demographics

  • Leukocytosis is very common.[2]

Age

  • Patients of all age groups may develop leukocytosis.
  • Normal white blood count differential changes with age.
  • Leukocytosis in neonates is more common, compared to children and adults.[2]

Gender

  • Leukocytosis affects men and women equally.

Race

  • There is no racial predilection for leukocytosis.

Risk Factors

  • Common risk factors in the development of leukocytosis, include:[2]
  • Physiologic processes (eg, stress, exercise, pregnancy)
  • Drugs (e.g.corticosteroids, lithium, beta agonists)
  • Trauma
  • Stress

Natural History, Complications and Prognosis

  • The majority of patients with leukocytosis are initially symptomatic.[3]
  • Early clinical features, include:[3]
  • Fever
  • Hyperhidrosis
  • Fatigue
  • Common complications of leukocytosis, include:[3]
  • Tumor lysis syndrome
  • Disseminated intravascular coagulopathy
  • Acute respiratory failure
  • Pulmonary hemorrhage
  • CNS infarction
  • Splenic infarction
  • Myocardial ischemia
  • Renal failure
  • Prognosis is generally depends on the underlying etiologies.[3]

Diagnosis

Symptoms

  • Leukocytosis is usually symptomatic.
  • Symptoms of leukocytosis are often unspecific, such as:[3]
  • Weight loss
  • Fevers of unknown origin
  • Hyperhidrosis
  • Chronic pain
  • Fatigue
  • Dyspnea
  • Malaise
  • Obtain history of the following:
  • Clinical features
  • Duration (e.g. days, weeks, months)
  • Remainder of complete blood count

Laboratory Findings

  • Laboratory findings consistent with the diagnosis of leukocytosis, include:[3]
  • White blood cell count above the normal range
  • Greater than 11,000 per mm3

Differentiating Leukocytosis from Other Diseases

Category Condition Etiology Mechanism Congenital Acquried Clinical manifestations Para−clinical findings Gold standard Associated findings
Demography History Symptoms Signs
Lab Findings
Physiologic Increased bone marrow production Demargination of peripheral blood neutrophils Appearance Fever Abdominal pain BP Asplenia Hepatosplenomegaly Lymphadenopathy Joint involvement Other CBC PBS Bone marrow exam ESR/CRP BUN/Cr LFT
Autonomous Reactive WBC HB Plt
Hematologic Hereditary neutrophilia[4] + + Rare autosomal dominant genetic disorder
  • Positive family history
Normal Nl + Nl Nl Nl Nl Nl Nl Molecular testing
Myeloproliferative neoplasms[5] + + + Elderly Exposure to ± + Nl + ↑/↓ ↑/↓ Nl Nl Bone marrow examination + clinical manifestation
Polycythemia vera[6] + + Mean age >60 years old + + Nl to ↑
  • Elevated normochromic, normocytic RBCs
  • Thrombocytosis
  • ≥ 10% immature myeloid precursors
  • Leukoerythroblastic picture
  • Increased myeloid:erythroid ratio due to granulocytic proliferation
Nl Nl Nl Bone marrow examination + clinical manifestation
Microangiopathic hemolytic anemia (MAHA)[7] + + + Any + + + NA Bone marrow examination + clinical manifestation
Leukoerythroblastosis[8] + + Any + Nl +
  • Early satiety
  • Fatigue
Nl Bone marrow biopsy
Immunology/

Rheumatology

Condition Etiology Physiologic Autonomous increased bone marrow production Reactive increased bone marrow production Demargination of peripheral blood neutrophils Congenital Acquried Demography History Appearance Fever Abdominal pain BP Asplenia Hepatosplenomegaly Lymphadenopathy Joint involvement Other signs WBC HB Plt PBS Bone marrow exam ESR/CRP BUN/Cr LFT Gold standard Associated findings
Leukocyte adhesion deficiency[9] + + Rare autosomal recessive, LAD II more in Middle East and Brazil
  • Positive family history
+ Nl ↓/↑
  • Leukocytosis
  • Leukocytosis
Nl Nl Nl Flow cytometry
Cryopyrin-associated periodic syndromes[10] + + Autosomal dominant autoinflammatory syndrome
  • Positive family history
  • Hive-like rash without itching
+ Nl + ↓/↑
  • Leukocytosis
  • Leukocytosis
Nl Genetic tests
Rheumatoid arthritis[11][12]
  • Immune mediated
+ + Any, more in young women, between 30-60 years old
  • Positive family history
  • Cigarette smoking
  • Obesity
  • Deformed joints
  • Rheumatoid nodules
+ Nl +
  • Leukocytosis
NA Nl Nl Clinical manifestation + positive anti-CCP antibodies
Juvenile onset rheumatoid arthritis[13]
  • Immune mediated
+ + Children under the age of 16
  • Positive family history
  • Blotchy rash on a child's arms and legs
+ Nl + +
  • Leukocytosis
NA Nl Nl Clinical manifestation + laboratory findings
Adult Still's disease
  • Immune mediated
+ + Rare autoimmune disease NA
  • Nonpruritic salmon-colored rash (usually over trunk or extremities while febrile)
+ Nl + +
  • Leukocytosis
NA Nl Nl Diagnosis of exclusion
Kawasaki disease
  • Immune mediated
+ + Autoimmune disease, more in Asian ethnicity boys NA
  • Diffuse macular-papular erythematous rash in the genital area, and red eyes, lips, palms or soles of the feet
+ + Nl + +
  • Strawberry tongue
  • Sore throat
  • Diarrhea
  • Bilateral conjunctival inflammation
  • Leukocytosis
NA Nl Nl Diagnostic criteria
IBD
  • Immune mediated
  • Mutation
+ + Autoimmune disease, more in young
  • Stress
  • Positive family history
  • Pyoderma gangrenosum
+ + Nl + + +
  • Vomiting
  • Diarrhea
  • Rectal bleeding
  • Leukocytosis
NA Nl Nl Colonoscopy and biopsy
  • Primary sclerosing cholangitis
  • Non-thyroidal illness syndrome
  • DVT
  • Bronchiolitis obliterans organizing pneumonia
Sarcoidosis
  • Immune mediated
  • Unknown
+ + Autoimmune disease, more in young African American women
  • Positive family history
  • Rashes, noduli, erythema nodosum, granuloma annulare, lupus pernio
+ + Nl + +

Bilateral hilar

+
  • Fatigue
  • Weight loss
  • Blurry vision
  • Shortness of breath
  • Cough
  • Leukocytosis
NA Nl Nl Diagnosis of exclusion
  • Interstitial lung disease
  • Systemic inflammatory disease
Chronic hepatitis
  • Infection
  • Autoimmune
  • Ischemic
+ + Elderly
  • Alcohol use
  • Acute infection
  • Jaundice
  • Ascites and peripheral edema
+ + + + +
  • Fatigue
  • Weight loss
  • Nausea and vomitting
  • Leukocytosis
NA Liver biopsy
  • Hirsutism
  • Amenorrhea
  • Coagulopathy
  • Hepatic encephalopathy
  • Esophageal varices
  • Hepatorenal syndrome
  • Liver cancer
Sweet syndrome
  • Immune mediated
  • Unknown
+ + Rare
  • Relapse and remission
  • Tender, red, well-demarcated papules and plaques on the head, neck, legs, and arms
+ + Nl + +
  • Conjunctivitis
  • Iridocyclitis
  • Oral aphthae
  • Leukocytosis
  • Papillary and mid-dermal mixed infiltrate of polymorphonuclear leukocytes with nuclear fragmentation and histiocytic cells
Nl Nl Diagnostic criteria
  • Cutaneous marker of systemic disease
  • Acute myelogenous leukemia
  • Immunologic disease
  • Slight increase in alkaline phosphatase
Acute gout
  • Elevated levels of uric acid in the blood
  • Diet
  • Genetic
+ + Older males
  • Alcohol use
  • Acute infection
  • Tophi
+ +
  • Fatigue
  • Leukocytosis
NA Nl Clinical manifestation
  • Arthritis
  • Urate nephropathy
Medication Condition Etiology Physiologic Autonomous increased bone marrow production Reactive increased bone marrow production Demargination of peripheral blood neutrophils Congenital Acquried Demography History Appearance Fever Abdominal pain BP Asplenia Hepatosplenomegaly Lymphadenopathy Joint involvement Other signs WBC HB Plt PBS Bone marrow exam ESR/CRP BUN/Cr LFT Gold standard Associated findings
Steroid
  • Release of granulocytes from the bone marrow
+ + + Any
  • Steroid use
  • Autoimmune disease
  • Malignancy
  • Obese
+ Nl to ↓ Nl to ↓ Nl Clinical manifestation + history of drug consumption
Filgrastim (Myeloid growth factor)
  • Release of granulocytes from the bone marrow
+ + + Any
  • Malignancy
  • Neutropenia
  • Hair loss
  • Local skin reactions at the site of injection
+ Nl to ↓ +
  • Cough
  • Chest pain
  • Vomiting
Nl to ↓ NA NA Nl Nl Clinical manifestation + history of drug consumption
  • Alveolar hemorrhage
  • Acute respiratory distress syndrome
Lithium
  • Unknown
+ + + Any
  • Bipolar disorder
  • Weight gain
  • Acne
  • Hand tremor
Nl Nl to ↓ NA NA Nl Nl Clinical manifestation + history of drug consumption
  • Extrapyramidal side effects
  • Euthyroid goitre
  • Hypothyroidism
  • Kidney damage
Catecholamines

(epinephrine)

  • Stimulation of bone marrow myelopoiesis
  • Egress into the circulation
+ + + Any
  • Acutely ill
  • Diaphoretic
Nl to ↓ Nl Nl Clinical manifestation + history of drug consumption
ATRA + + + Any
  • Acne
  • Acute promyelocytic leukemia
  • Skin dryness
  • Hair loss
Nl
  • Shortness of breath
  • Headache
  • Numbness
  • Depression
  • Itchiness
  • Vomiting
  • Muscle pain
  • Vision changes
Nl Nl NA NA Nl Clinical manifestation + history of drug consumption
  • Teratogen
  • Thrombosis
  • Benign intracranial hypertension
  • Hypercholesterolemia
  • Liver damage
Other Condition Etiology Physiologic Autonomous increased bone marrow production Reactive increased bone marrow production Demargination of peripheral blood neutrophils Congenital Acquried Demography History Appearance Fever Abdominal pain BP Asplenia Hepatosplenomegaly Lymphadenopathy Joint involvement Other signs WBC HB Plt PBS Bone marrow exam ESR/CRP BUN/Cr LFT Gold standard Associated findings
Infections Infection + + + + Any
  • Close contact
  • Immunodeficiency
  • Acutely ill
+ + Nl to ↓ ± ± ±
  • Fatigue
  • Nausea and vomiting
Nl Nl Clinical manifestation+ culture
  • Depends on etiology
Allergy
  • Unknown
  • Activation of chloride transport
+ + + + Any
  • Acutely ill
  • Diaphoretic
Nl to ↓ Nl Nl Clinical manifestation
Post splenectomy
  • Unknown
+ + + Any
  • Normal
± Nl + Nl Nl Clinical manifestation
Cigarette smoking + + + Any Nl NA NA Nl Nl Nl Clinical manifestation
Stress/exercise
  • Reduced plasma volume
+ + + Athlete
  • Exercise
  • Normal
Nl Nl Nl Clinical manifestation
Infancy Physiologic + + Infancy
  • Normal
Nl NA NA Nl Nl Nl Clinical manifestation
Pregnancy Physiologic + + Pregnancy
  • Normal
Nl NA NA Nl Nl Nl Clinical manifestation
Platelet clumping Spurious + Any
  • Normal
Nl Nl
  • Cytoplasmic fragments
Nl Nl Nl Nl Clinical manifestation
Mixed cryoglobulinemia Spurious + Any
  • Atypical cutaneous ulcers
  • Palpable purpura
Nl + Nl to ↓
  • Cytoplasmic fragments
Nl Nl Nl Nl Skin biopsy
Category Condition Etiology Physiologic Autonomous increased bone marrow production Reactive increased bone marrow production Demargination of peripheral blood neutrophils Congenital Acquried Demography History Appearance Fever Abdominal pain BP Asplenia Hepatosplenomegaly Lymphadenopathy Joint involvement Other signs WBC HB Plt PBS Bone marrow exam ESR/CRP BUN/Cr LFT Gold standard Associated findings

Treatment

Medical Therapy

  • The treatment for leukocytosis will depend on the underlying condition.[3]

References

  1. 1.0 1.1 Chabot-Richards DS, George TI (2014). "Leukocytosis". Int J Lab Hematol. 36 (3): 279–88. doi:10.1111/ijlh.12212. PMID 24750674.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 Abramson N, Melton B (2000). "Leukocytosis: basics of clinical assessment". Am Fam Physician. 62 (9): 2053–60. PMID 11087187.
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Leukocytosis. Wikipedia. https://en.wikipedia.org/wiki/Leukocytosis Accessed on May 23, 2016
  4. Herring, William Benjamin; Smith, Laurin Gresham; Walker, Richard Isley; Herion, John Carroll (1974). "Hereditary neutrophilia". The American Journal of Medicine. 56 (5): 729–734. doi:10.1016/0002-9343(74)90642-1. ISSN 0002-9343.
  5. Tefferi A (February 2010). "Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain". Am. J. Hematol. 85 (2): 93–4. doi:10.1002/ajh.21614. PMID 20052751.
  6. Boiocchi L, Gianelli U, Iurlo A, Fend F, Bonzheim I, Cattaneo D, Knowles DM, Orazi A (November 2015). "Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications". Mod. Pathol. 28 (11): 1448–57. doi:10.1038/modpathol.2015.100. PMID 26336886.
  7. Morton JM, George JN (June 2016). "Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer". J Oncol Pract. 12 (6): 523–30. doi:10.1200/JOP.2016.012096. PMID 27288467.
  8. Canbolat Ayhan A, Timur C, Ayhan Y, Kes G (June 2014). "Leukoerythroblastosis Mimicking Leukemia: A case report". Iran J Pediatr. 24 (3): 332–3. PMC 4276592. PMID 25562031.
  9. Levy-Mendelovich S, Rechavi E, Abuzaitoun O, Vernitsky H, Simon AJ, Lev A, Somech R (April 2016). "Highlighting the problematic reliance on CD18 for diagnosing leukocyte adhesion deficiency type 1". Immunol. Res. 64 (2): 476–82. doi:10.1007/s12026-015-8706-5. PMID 26434744.
  10. Labrousse M, Kevorkian-Verguet C, Boursier G, Rowczenio D, Maurier F, Lazaro E, Aggarwal M, Lemelle I, Mura T, Belot A, Touitou I, Sarrabay G (September 2018). "Mosaicism in autoinflammatory diseases: Cryopyrin-associated periodic syndromes (CAPS) and beyond. A systematic review". Crit Rev Clin Lab Sci. 55 (6): 432–442. doi:10.1080/10408363.2018.1488805. PMID 30035647.
  11. Scott DL, Wolfe F, Huizinga TW (September 2010). "Rheumatoid arthritis". Lancet. 376 (9746): 1094–108. doi:10.1016/S0140-6736(10)60826-4. PMID 20870100.
  12. Glant TT, Mikecz K, Rauch TA (February 2014). "Epigenetics in the pathogenesis of rheumatoid arthritis". BMC Med. 12: 35. doi:10.1186/1741-7015-12-35. PMC 3936819. PMID 24568138.
  13. Naz S, Mushtaq A, Rehman S, Bari A, Maqsud A, Khan MZ, Ahmad TM (June 2013). "Juvenile rheumatoid arthritis". J Coll Physicians Surg Pak. 23 (6): 409–12. doi:06.2013/JCPSP.409412 Check |doi= value (help). PMID 23763801.


Template:WikiDoc Sources